As more stories emerge about progressive multifocal leukoencephalopathy (PML) in patients using the psoriasis drug Raptiva (efalizumab), the FDA
has issued a public health advisory. Raptiva is a biologic agent and in October 2008, a black box warning was added to the product label. Raptiva is manufactured by Genentech.
Post a Comment